Hepatic solitary fibrous tumors (SFTs) are mostly benign and rare because of information regarding the clinical symptoms, treatment, and prognosis of their malignant forms is currently lacking. A literature review concerning malignant SFTs revealed that there were a few cases where patients experienced abdominal right upper quadrant (RUQ) pain as their first clinical symptom, and metastases were found after being diagnosed with hepatic SFT. Here, we report a patient who was previously healthy without any clinical symptoms such as RUQ pain or weight loss, but had the appearance of a metastatic mass as the first clinical presentation before a primary hepatic SFT was detected
IntroductIon
Solitary fibrous tumors (SFTs) are rare mesenchymal neoplasms usually found in the pleural cavity. 1 However, they can also originate in other body parts, including the retroperitoneum, trunk, extremities, head, and neck. SFT are mostly benign. 2 Hepatic SFT is rare and is reported to be benign. 3 Only a few cases of malignant hepatic SFT have been reported, and right upper quadrant (RUQ) pain, weight loss, and loss of consciousness are some of the first symptoms to appear. 4, 5 According to the available literature, the skull base, lung, and vertebrae showed metastases after malignant hepatic SFT was diagnosed. Here, we report a case of malignant hepatic SFT with metastatic subcutaneous mass as the first symptom in a previously healthy patient without abdominal or systemic symptoms, along with a literature review. cASE rEPort
Clinical findings
In June 2017, a 69-year old woman was admitted to the hospital with a chief complaint of a mass in the right flank region. The patient was previously healthy without any past history, abdominal pain, anorexia, or weight loss findings. On physical examination, a 3×2 cm-sized, non-tender, ovalshaped mass was observed in the right flank subcutaneous region. Laboratory test results revealed elevated alkaline phosphatase (139 IU/L), gamma-glutamyltransferase (547 IU/L), aspartate aminotransferase (52 IU/L), and alanine aminotransferase (74 IU/L) levels, whereas carcinoembryonic antigen, carbohydrate antigen 19-9, and alpha-fetoprotein levels were within the normal range. its depth and size were evaluated. An incidental finding of a 14× 11×10 cm-sized heterogeneous enhanced mass was also observed in the right hepatic lobe (Fig. 1B) . The mass was evaluated using magnetic resonance imaging (MRI). Early arterial enhancement findings were noted in the liver third-phase MRI arterial phase ( Fig. 2A ), while delayed progress enhancement findings were observed in the portal phase ( Fig. 2B ), which was interpreted as a suspicious hypervascular sarcoma.
Liver histological examination was performed using fine needle biopsy; the cells revealed similar morphology to that of spindled tumor cells with a typical "staghorn" vascular pattern of malignant SFT (Fig. 3A) . For clinical staging, excisional biopsy of the flank mass was conducted; the histological analysis of the lesion was a "patternless" disposition with typical ectatic and irregularly shaped vessels ( Fig. 3B ). Additionally, in high power, tumor cells are ovoid to spindle shaped with relatively uniform and bland cytology, and increased mitotic activity was identified (Fig. 3C ). The cluster of differentiation (CD) 34 immunohistochemical expression was strong and diffuse ( Fig. 3D ). 
Treatment progress
Chest CT showed a suspected pulmonary metastasis (Fig. 4 ).
The patient refused palliative surgery and thus, received three cycles of chemotherapy (CTx) that included adriamycin (30 mg on days 1-3), ifosfamide (2,355 mg on days 2-4), and mesna (1,256 mg IV 0 hours, 3 hours, and 6 hours after ifosfamide).
Adjunctive radiation therapy was not administered. Despite
CTx, the tumor rapidly enlarged and pulmonary metastases were detected with weight loss. The patient died in June, 2018. and, occurred in both the left and right lobes, 3 but the size of the malignant SFT was frequently larger (14-32 cm) and was mostly found in the right lobe.
Resection was performed in most malignant SFT cases, and additional CTx was performed in some cases. In our case, when the patient was admitted, subcutaneous and lung metastases were already present; therefore, performing surgery was impossible. Thus, only CTx was administered.
Many authors believe that postoperative adjuvant CTx and radiotherapy are helpful in unresectability or malignancy cases. 6, 7 Currently, the combination of doxorubicin and ifosfamide is the standard systemic CTx regimen for many softtissue sarcoma subtypes. There was a report of a malignant SFT case in which CTx showed a response. 8 Archontaki et al. 7 and we used CTx, including adriamycin, ifosfamide, and mensa; however, there was no response. Additional investigations in a controlled, prospective trial on the use of CTx In our case, a similar morphology of spindled tumor cells with a typical "staghorn" vascular pattern was found in the liver histological findings. The tumor was well-circumscribed, with increased cellularity, a focal area of necrosis at low power, and increased mitotic activity at high power in the flank mass. Furthermore, CD34 immunohistochemical expression was strong and diffuse. Based on these characteristics, hepatocellular malignancy could be suspected. However, the CD34 antibody is not SFT specific and could be positive in both angiosarcoma and gastrointestinal stromal tumors. 9 Because malignant SFTs share many features with other neoplasms, can occur at practically any site, and have no specific immunohistochemical profile, they can be extremely difficult to distinguish from other spindle cell neoplasms. 12 The diagnosis of malignant SFT was made based on the typical "staghorn" vascular pattern observed in the liver biopsy and the increased mitosis cell cytology of the subcutaneous biopsy.
In summary, malignant hepatic SFT is a rare neoplasm for which clinical symptoms, diagnosis, treatment, and prognosis are unclear. We report a case with a clinical symptom (painless metastatic subcutaneous mass) and metastatic course that are different from previous reports. 
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